logo
Plus   Neg
Share
Email

Stock Watch: Agios Pharma Rises On Positive Cholangiocarcinoma Trial Data

Shares of Agios Pharmaceuticals Inc. (AGIO) rose more than 18% in extended trading on Wednesday, following positive results from its global phase III trial of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation.

Cholangiocarcinoma is a group of cancers that begin in the bile ducts. (Source: NIH). Advanced cholangiocarcinoma is a life-threatening disease with no currently approved treatment options.

In the phase III trial, dubbed ClarIDHy, treatment with TIBSOVO demonstrated a statistically significant improvement in progression-free survival compared with patients who received placebo.

TIBSOVO was approved by the FDA for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation last July. The drug generated $13.84 million of net product revenue from U.S. sales of TIBSOVO in 2018.

The Company plans to submit a supplemental new drug application for TIBSOVO in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.

AGIO closed Wednesday's trading at $47.35, down 1.00%. In after-hours, the stock was up 18.80% to $56.25.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Casino operator MGM Resorts International said it was the victim of a data breach in 2019 after a report claimed that the details of more than 10.6 million hotel guests were exposed. Technology website ZDNet reported about the incident late on Wednesday, saying that the personal details of more than 10.6 guests who stayed at MGM Resorts hotels were published on a hacking forum this week. Amid the ongoing troubles with its 737 MAX commercial planes grounding since March 2019, Boeing (BA) has secured a five-year U.S. Air Force contract to sustain and modernize the Global Decision Support System, or GDSS. The financial terms of the deal were not disclosed. The contract was awarded to Tapestry Solutions, part of Boeing Global Services. Reinsurer Swiss Re reported Thursday significantly higher profit in fiscal 2019 driven by higher premiums mainly in property and casualty businesses, despite heavy natural catastrophe losses. The company also said it will propose higher dividend and share buyback of up to 1 billion Swiss Francs. Swiss Re were losing around 4 percent in trading.
Follow RTT
>